1 withdrawn. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Toxicity: new trials by email Literature Review of Toxicity trials Research Report on Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma pegylated liposomal doxorubicin, pirarubicin - Progression-free Survival, Overall Survival | Phase 2 / Phase 3 | Withdrawn | Peking University People's Hospital | 2017-11-06 | 2020-05-19 |
Sarcoma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Connective and Soft Tissue (1)
liposomal doxorubicin (1) · pirarubicin (1)
Peking University People's Hospital (1)
China (1)